Lifitegrast sodium
Drug type
Small molecule
- Listing at source
- Listed
- Drug type
- Small molecule
- Drug name
- Lifitegrast sodium
- Molecular weight
- 637.47
- Structure (SMILES)
- CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)[O-])c1.[Na+]
- l phenylalanine n 2 6 benzofuranylcarbonyl 5 7 dichloro 1 2 3 4 tetrahydro 6 isoquinolinyl carbonyl 3 methylsulfonyl sodium salt 1 1
- L-PHENYLALANINE, N-((2-(6-BENZOFURANYLCARBONYL)-5,7-DICHLORO-1,2,3,4-TETRAHYDRO-6-ISOQUINOLINYL)CARBONYL)-3-(METHYLSULFONYL)-, SODIUM SALT (1:1)
- lifitegrast sodium
- Lifitegrast sodium
- LIFITEGRAST SODIUM [USAN]
- Lifitegrast sodium [WHO-DD]
- lifitegrast sodium usan
- lifitegrast sodium who dd
- sar 1118 023
- SAR 1118-023
- SAR-1118-023
- Sodium (2S)-2-({[2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-yl]carbonyl}amino)-3-[3-(methylsulfonyl)phenyl]propanoate
- sodium 2s 2 2 benzofuran 6 ylcarbonyl 5 7 dichloro 1 2 3 4 tetrahydroisoquinolin 6 yl carbonyl amino 3 3 methylsulfonyl phenyl propanoate
- CAS registry numbers
- 1119276-80-0
- ChEMBL ID
- CHEMBL2048409
- InChIKey
- BPWOKOSRORLLIN-BQAIUKQQSA-M
- PubChem compound IDs
- 56963348
- FDA ingredient codes (UNII)
- QG18FLP1KP
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -ast
Open Targets mechanisms
- Mechanism
- Integrin alpha-L/beta-2 (LFA-1) antagonist
- Action type
- Antagonist
- Target
- Integrin alpha-L/beta-2 (LFA-1)
- Condition identifier
- HP_0001097
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003799
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005328
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005642
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006733
- Highest recorded phase
- 4
- Event
- abdominal pain
- Reports
- 4
- Reporting signal score
- 26.5742
- Event
- abnormal sensation in eye
- Reports
- 18
- Reporting signal score
- 48.6528
- Event
- anaemia
- Reports
- 1
- Reporting signal score
- 35.9026
- Event
- arthralgia
- Reports
- 2
- Reporting signal score
- 46.0898
- Event
- asthenia
- Reports
- 4
- Reporting signal score
- 38.8517
- Event
- asthenopia
- Reports
- 15
- Reporting signal score
- 38.5092
- Event
- back pain
- Reports
- 4
- Reporting signal score
- 18.0137
- Event
- burning sensation
- Reports
- 31
- Reporting signal score
- 18.3043
- Event
- constipation
- Reports
- 4
- Reporting signal score
- 17.0004
- Event
- corneal abrasion
- Reports
- 6
- Reporting signal score
- 14.969
- Event
- corneal disorder
- Reports
- 9
- Reporting signal score
- 19.1738
- Event
- decreased appetite
- Reports
- 4
- Reporting signal score
- 16.3723
- Event
- depression
- Reports
- 1
- Reporting signal score
- 25.1915
- Event
- diarrhoea
- Reports
- 10
- Reporting signal score
- 63.9608
- Event
- drug interaction
- Reports
- 3
- Reporting signal score
- 26.3372
- Event
- dry eye
- Reports
- 165
- Reporting signal score
- 449.044
- Event
- dysgeusia
- Reports
- 315
- Reporting signal score
- 834.743
- Event
- dyspnoea
- Reports
- 35
- Reporting signal score
- 18.5158
- Event
- erythema of eyelid
- Reports
- 12
- Reporting signal score
- 24.2809
- Event
- eye complication associated with device
- Reports
- 4
- Reporting signal score
- 15.7243
- Event
- eye discharge
- Reports
- 81
- Reporting signal score
- 274.554
- Event
- eye disorder
- Reports
- 66
- Reporting signal score
- 134.128
- Event
- eye infection
- Reports
- 13
- Reporting signal score
- 17.4097
- Event
- eye injury
- Reports
- 11
- Reporting signal score
- 29.2452
- Event
- eye irritation
- Reports
- 486
- Reporting signal score
- 1,891.73
And 77 more, listed on the interactive page.
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 133.99
- Calculated partition coefficient (ALogP)
- 4.77
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 42
- Molecular formula
- C29H23Cl2N2NaO7S
- Monoisotopic mass
- 636.0500719
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 0
Related records
Trials (26)
- A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
- A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
- A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
- A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
- Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days
- Effect of Lifitegrast 5% on Tear Film Markers
- Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms
- Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
- Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
- Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease
- Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
- Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness
- Lifitegrast Eye Drops in Healthy Subjects：Phase I Study
- Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra
- Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
- Safety Study of Lifitegrast to Treat Dry Eye
- The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study